|
|
- こうしょ あざみ
- 5 years ago
- Views:
Transcription
1
2 1098 CHEMOTHERAPY SEPT. 1992
3 VOL. 40 NO A) B) Fig. 1. Construction the expression plasmids for the wild-type Escherichia coli GyrA (A) and GyrB (B) proteins.
4 Table 1. Quinolone-resistant mutations in the gyra gene Escherichia coli KL 16
5 VOL.40 NO キ ノ ロ ン薬 の ジ ャイ レ ー ス 阻 害 作 用 機 作 ー タ 省 略) 第1の タ イ プ の 変 異 で は 荷 電 と局 所 構 造 の 変 化 が 推 測 さ れ,第2の タ イ プ の 変 異 で は,荷 電 の 変 化 の み が起 きる と推 測 され る(デ ー タ省 略) 3.精 製GyrAお よびGyrB蛋 大 腸 菌KL16株(野 生 型),N-51株(gyrA変 株),N-24株(第1タ 31株(第2タ gyraお 白 の純 度 と比 活 性 イ プ 砂rB変 イ プgyrB変 よ びgyrB遺 異 株)よ よ びN- り ク ロ ー ン化 し た 伝 子 を 有 す る プ ラ ス ミ ドか ら, 材 料 と方 法 の 項 で述 べ た よ うに,発 築 しGyrAお 異 異 株)お よ びGyrB蛋 現 プ ラ ス ミ ドを構 白 を 大 量 生 産 し,精 製 し た 野 生 型 大 腸 菌KL 16株 お よ び キ ノ ロ ン耐 性gyrA変 異 株N-51のgyrA遺 (以 後AKL16お 伝 子 か ら生 産 さ れ たGyrA蛋 よ びAN51と キ ノ ロ ン耐 性gyrB変 記 載)お 異 株Nー24,N-31の 伝 子 か ら生 産 さ れ たGyrB蛋 よ びBN31と 白(以 記 載)はSDS-ポ 各gyrB遺 後BKL16,BN24お リ ア ク リル ア ミ ド ゲ ル 電 気 泳 動 に よ る チ ェ ッ クで は,90%以 た (Fig.2) し か し,DNAス 上 の純 度 で あ っ ーパ ー コ イ リング活 性 で 測 定 し た 各 蛋 白 の 比 活 性 はAKL16: 単 mg,an51: 単 で あ り,GyrB蛋 1/20 1/100程 Fig. 2. 白 の比 活 性 はGyrA蛋 位/mg 白 の比 活 性 の 度 で あ っ た この 結 果 はGyrB蛋 purified 4scherichia were 位/ 位/mg,BN31= 単 SDS-polyacrylamide gram 位/ 位/mg,BKL16:8,5 104単 mg,bn24: 単 coli. subjected gel GyrA and About 1-2ƒÊg to electrophoresis. 白 よ びKL16株, 白標 electrophoreto- GyrB proteins proteins each SDS-polyacrylamidegel KL 16; 2, GyrA N-51; 1, 3, GyrA GyrB KL 16; 4, GyrB N-24; 5, GyrB N-31.
6 1102 CHEMOTHERAPY SEPT Table 3. Quinolone sensitivity wild-type and mutant Escherichia coli gyrases in the supercoiling reaction KL16: E. coli KL 16 having the wild-type gyra and gyrb genes. N-51: E. coli N-51 having the mutant gyra gene (Ser-83 to Leu) N-24: E. coil N-24 having the type 1 mutant gyrb gene (Asp-426 to Asn). N-31: E. coli N-31 having the type 2 mutant gyrb gene (Lys-447 to Glu). pbr 322 and phy 300 PLK: plasmids for E. coli and B. subtilis, respectively.
7 Table 4. Binding 3H-enoxacin with the gyrase-dna complexes a Kd values for the binding enoxacin were estimated by Scatchard plot analyses.
8 1104 CHEMOTHERAPY SEPT, ) Gellert M, Mizuuchi K, O'Dea M H, Ito T, Tomizawa J: Nalidixic acid resistance: a second. genetic character involved in DNA gyrase activity, Proc. Natl. Acad. Sci. USA 74: 4772 `4776, ) Sugino A, Peebles C L, Kreuzer K N, Cozzarelli N R: Mechanism action nalidixic acid: purification Escherichia coil nala gene product and its relationship to DNA gyrase and a novel nicking-closing activity. Proc. Natl. Acad. Sci. USA 74: 4772 `4776, ) Wolfson J S, Hooper D C, Swartz M N. Mechanism action and resistance to quinolone antimicrobial agents, In Quinolone antimicrobial agents (Wolfson J S, Hooper DC eds.), p 5 `34, American Society for Microbiology, Washington, D.C ) Shen L L, Pernet A G. Mechanism inhibition DNA gyrase by analogues nalidixic acid: the target the drugs is DNA. Proc. Natl. Acad. Sci. USA 82:307 `311, ) Shen L L, Kohlbrenner W E, Weigl D, Baranowski J: Mechanism quinolone inhibition DNA gyrase. J. Biol. Chem. 264: 2973 `2978, ) Shen L L, Mitscher L A, Sharma P N O'Donnell T J, Chu D W T, Cooper C S, Rosen T, Pernet A G: Mechanism inhibition DNA gyrase by quinolone antibacterials: a cooperative drug- DNA binding model. Biochemistry 28: 3886 ` ) Yoshida H, Kojima T, Yamagishi J, Nakamura S: Quinolone-resistant mutations the gyra gene Escherichia coli. Mol. Gen. Genet. 211: 1 `7, ) Yamagishi J, Yoshida H, Yamayoshi M, Nakamura S: Nalidixic acid-resistant mutations the gyrb gene Escherichia coli. Mol. Gen. Genet. 204: 367 `373, ) Yoshida H, Bogaki M, Nakamura M, Nakamura S: Quinolone resistance-determining region in the DNA gyrase gyra gene Escherichia coli. Antimicrob. Agents Chemother. 34: 1271 `1272, ) Yoshida H, Bogaki M, Nakamura M, Yamanaka L M, Nakamura S: Quinolone resistancedetermining region in the DNA gyrase gyrb gene Escherichia coli. Antimicrob. Agents Chemother. 35: 1647 `1650, ) Wilkie N M, Clements J B, Boll W, Mantei N, Lonsdale D, Weissmann C: Hybrid plasmids containing an active thymidine kinase gene Herpes simplex virus I. Nucleic Acids Res. 7: ) Holmes D S, Quigley M: A rapid boiling method for the preparation bacterial plasmids. Anal. Biochem. 114: 193 `197, ) Messing J: New M 13 vectors for cloning. Methods in Enzymol. 101: 20 `78, 1983
9 VOL. 40 NO ) Miller J H: Experiments in molecular genetics. Cold Spring Harbor Laboratory, Cold Spring Harbor N Y, ) Yamada M, Furutani Y, Notake M, Yamagishi J, Yamayoshi M, Fukui T, Nomura H, Komiya M, Kuwashima J, Nakano K, Sohmura Y, Nakamura S: Efficient production human tumor necrosis factor in Escherichia coli. J. Biotechnol. 3: 141 `153, ) Gellert M, Fisher L M, O'Dea M H: DNA gyrase: purification and catalytic properties a fragment gyrase B protein. Proc. Natl. Acad. Sci. USA. 76: 6289 `6293, ) Sato K, Inoue Y, Fujii T, Aoyama H, Inoue M, Mitsuhashi S: Purification and properties DNA gyrase from a fluoroquinolone-resistant strain Escherichia coli, Antimicrob. Agents Chemother, 30: 777 `780, ) Horowitz D S, Wang J C: Mapping the active site tyrosine Escherichia coli. DNA gyrase. J. Biol. Chem. 262: 5339 `5344, ) Adachi T, Mizuuchi M, Robinson E A, Appella E, O'Dea, Gellert M. Mizuuchi K: DNA sequence the E. coli gyrb gene: application a new sequencing strategy. Nucleic Acids Res, 15: 771 ` 784, ) Brown P O, Peebles C L, Cozzarelli N R: A topoisomerase from Escherichia coli related to DNA gyrase. Proc. Natl. Acad. Sci, USA. 76: 6110 `6114, 1979 Mechanism action quinolones on Escherichia coli DNA gyrase Hiroaki Yoshida Bioscience Research Laboratories, Dainippon Pharmaceutical Co., Ltd., Enoki 33-94, Suita, Osaka 564, Japan Seven point mutations were detected in 10 quinolone-resistant gyra mutants Escherichia coli KL 16, i.e., Ser-83 to Leu (4 strains), Ser-83 to Trp, Asp-87 to Asn, Gly-81 to Cys, Ala-84 to Pro, Ala -67 to Ser and Gln-106 to His. Among 13 quinolone-resistant gyrb mutants E. coli KL 16, 2 point mutations were detected, Asp-426 to Asn (9 strains) and Lys-447 to Glu (4 strains). The former mutation (type 1) confers resistance to all the quinolones tested, while the latter mutation (type 2) results in resistance to acidic quinolones and hypersusceptibility to amphoteric quinolones. Almost all the gyra and gyrb mutations are believed to occur on protein surfaces, based on cpmputer analysis. Mutant DNA gyrases reconstituted from wild-type GyrA (or GyrB) and mutant GyrB (or GyrA) proteins were resistant to or hypersensitive to quinolones as expected from the MICs for the corresponding mutants. 3H-enoxacin was bound to gyrase-dna complexes but not to gyrase alone or to DNA alone. The amount enoxacin bound to the GyrA mutant gyrase-dna complex was the same as that bound to the wild-type gyrase-dna complex, but the binding affinity to the former was one-tenth the binding to the latter. The amount enoxacin bound to the type 1 GyrB mutant gyrase-dna complex was one-seventh that bound to the wild-type complex. Enoxacin was bound to the type 2 GyrB mutant gyrase-dna complex in the same amount as to the wild-type complex with five-times greater affinity for the former than the latter. These data suggest that quinoloneresistance DNA gyrase can be explained by the decreased amount quinolone binding or decreased quinolone binding affinity to gyrase-dna complexes.
CHEMOTHERAPY 52 MAY d a a. Normal S. aureus d Đg/ml, 2h; e b b Đg/ml, Abnormal e. division lh; Abnormal thickening division cross f c. 1
Levloxacin V.:1 Z iiiir fa L CHEMOTHERAPY 52 MAY d a a. Normal S. aureus d. 0.39 Đg/ml, 2h; e b b. 0.10 Đg/ml, Abnormal e. division lh; Abnormal thickening division cross f c. 1992 0.39 Đg/ml, and Fig.
More informationJUNE 1988
JUNE 1988 VOL.36 S-2 CHEMOTHERAPY Table 1. Antibacterial activity of NY-198 against standard strains of bacteria By the agar-dilution method (inoculum: 106 CFU/ml) JUNE 1988 Fig. 3. Antibacterial activity
More information1_alignment.ppt
" " " " n " n n " n " n n n " n n n n " n LGPSSKQTGKGW-SRIWDN! + +! LN-ITKSAGKGAIMRLGDA! " n -------TGKG--------!! -------AGKG--------! " n w w w " n w w " " " 11 12 " n w w w " n w w A! M! O! A!
More informationKey words : R-plasmid, Urinary tract infection, E. coli Fig. 1. MIC distribution against E. coli isolated from urinary tract (366 strains) and isolation - frequencies of drug-resistant strains Table 1.
More informationVOL.47 NO.5 Table 1. Susceptibility distribution of Ĉ- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus
MAY 1999 VOL.47 NO.5 Table 1. Susceptibility distribution of ƒà- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus (oxacillin MIC: 4ƒÊg/ ml) FMOX: flomoxef,
More information1272 CHEMOTHERAPY MAR. 1975
1272 CHEMOTHERAPY MAR. 1975 VOL. 23 NO. 3 CHEMOTHERAPY 1273 Fig. 2 Minimal inhibitory concentration of aminoglycosides against 50 strains of Klebsiella Fig. 1 Minimal inhibitory concentration of aminoglycosides
More informationFig. 1. Structures of NM394, NAD-358 and NAD-245 Fig. 2. Typical HPLC chromatograms of NM394 in human plasma by organic solvent extraction method (a): Blank plasma (b): Plasma spiked with NM394 and internal
More informationCHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study
CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study VOL. 41 S 1 Table 2. Levels (Đg/ml or Đg/g) of S-1006 in serum, bile, and tissue (gallbladder) after oral administration
More informationyakugaku-kot.ppt
2009 Masaaki Kotera kot@kuicr.kyoto-u.ac.jp 2 I II / A () B1 () B2 B12 C () D A D () () () () DNA 5- http://www.genome.jp/kegg/pathway.html KEGG PATHWAY Database Xenobiotics biodegradation http://www.genome.jp/kegg/pathway.html
More informationCHEMOTHERAPY APR Fig. 1 Chemical structure of cefotetan (CTT, YM09330)
CHEMOTHERAPY APR. 1982 Fig. 1 Chemical structure of cefotetan (CTT, YM09330) VOL.30 S-1 CHEMOTHERAPY Fig. 2 Comparison of standard curves of CTT on various test organisms by cylinder plate method Column
More informationFig. 1 Chemical structure of DL-8280
Fig. 1 Chemical structure of DL-8280 Fig. 2 Susceptibility of cl in ical isolates to DL4280 Fig. 5 Susceptibility of clinical isolates to DL-8280 Fig. 3 Susceptibility of clinical isolates to DL-8280 Fig.
More informationVOL.48 NO.7 lase negative staphylococci, Escherichia coli, Klebsiella spp., Citrobacter freundii, Enterobacter spp., indole-positive Proteus, Serratia
ceftazidime, cefpirome, cefepime, cefoperazone/sulbactam (2: 1), imipenem Staphylococcus aureus oxacillin coagulase negative staphylococci Escherichia coli piperacillin Klebsiellac spp. Citrobacter Pseudomonas
More informationCHEMOTHERAPY aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Prote
aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Proteus mirabilis 3.13, Proteus vulgaris 1.56, Citrobacter freundii 0.39,
More informationb) Gram-negative bacteria Fig. 2 Sensitivity distribution of clinical isolates : E. coli Fig. 3 Sensitivity distribution of clinical isolates : Pseudomonas Fig. 1 Sensitivity distribution of clinical isolates
More informationKey words:fatty acid,plant oil,staphylococcus aureus,skin care, atopic dermatitis
Key words:fatty acid,plant oil,staphylococcus aureus,skin care, atopic dermatitis growth was monitored at 660 nm with a biophotorecorder. Table 1.Relative inhibitory effects of fatty acids,plant oils,
More informationCHEMOTHERAPY JUNE 1987 Table1 Media used *BHIB, brain heart infusion broth (Difco); /3 -NAD, S -nicotinamidoadeninedinucleotide (Sigma Chemical Co.);
VOL.35 S-2 CHEMOTHERAPY Fig.1 Chemical structure of carumonam CHEMOTHERAPY JUNE 1987 Table1 Media used *BHIB, brain heart infusion broth (Difco); /3 -NAD, S -nicotinamidoadeninedinucleotide (Sigma Chemical
More informationTable 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates
Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates Table 2-1. Summary of patients treated with grepafloxacin for respiratory infection 1) Out: outpatient,
More information表1.eps
Vol.1 C ontents 1 2 cell-free EMBO J Proc. Natl. Acad. Sci. USA NatureEMBO J 3 RNA NatureEMBO J Nature EMBO J 4 5 HCV HCV HCV HCV RNA HCV in situ 6 7 8 Nat Struct Mol Biol J Biol Chem Nat Commun J Virol
More informationCHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Kle
VOL. 29 NO.8 CHEMOTHERAPY 865 CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Klebsiella pneumoniae GN-69
More informationClostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile
Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile Key words: temafloxacin, TA-167, Bacteroides fragilis,
More information日本化学療法学会雑誌第57巻第1号
In vitro Streptococcus pneumoniae Escherichia coli in vitro Streptococcus pneumoniae Escherichia coli µs. pneumoniae E. coli µ Key words in vitrostreptococcus pneumoniae Escherichia coli Escherichia coli
More informationFig.1 Chemical structure of BAY o 9867
Fig.1 Chemical structure of BAY o 9867 CHEMOTHERAPY 43 Table 3 Antibacterial spectrum of gram negative bacteria Medium:Heart infusion agar (Nissui) Method:Agar dilution (Streak) CHEMOTHERAPY DEC 1985
More informationVOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains )
CHEMOTHERAPY OCT. 1984 Fig. I Chemical structure of CTRX VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains ) CHEMOTHERAPY Fig. 3 Cumulative
More informationJan THE JAPANESE JOURNAL OF ANTIBIOTICS XL-1 Table 1. Outline of administering doses, routes and sampling times *: 4 ml/hr/kg Bacillus subtilis
THE JAPANESE JOURNAL OF ANTIBIOTICS XL-1 Jan. 1987 Jan. 1987 THE JAPANESE JOURNAL OF ANTIBIOTICS XL-1 Table 1. Outline of administering doses, routes and sampling times *: 4 ml/hr/kg Bacillus subtilis
More informationNetsu Sokutei 19 (4) Thermal Transitions and Stability of Fatty Acid-Containing and Defatted Bovine Serum Albumin (BSA) Michiko Kodama, Shinji
Netsu Sokutei 19 (4) 163-169 Thermal Transitions and Stability of Fatty Acid-Containing and Defatted Bovine Serum Albumin (BSA) Michiko Kodama, Shinji Takebayashi, Shun-ichi Kidokoro* and Hatsuho Uedaira**
More informationDatabase Center for Life Science Online Service Miho Shimizu, [Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sap
Miho Shimizu, [Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo 060, Japan] Molecular Basis of Triplet Repeat Diseases : Genetic Instabillity and Unusual DNA
More informationCHEMOTHERAPY
CHEMOTHERAPY CHEMOTHERAPY Table 1 Antibacterial activity of BRL 28500 against standard strains of bacteria Fig, 1 Sensitivity distribution of ABPC-resistant E. coli isolated from urinary tract Fig. 2 Sensitivity
More informationdihydrostreptomycin(sm), sulfanilamide(sa), kanamycin(km), paromomycin(prm), fradiomycin(frm), ampicillin(apc), cephaloridine (CER), nalidixic acid(na
Key words: Shigella, Bacterial resistance against entibiotics. Distribution of R factors dihydrostreptomycin(sm), sulfanilamide(sa), kanamycin(km), paromomycin(prm), fradiomycin(frm), ampicillin(apc),
More information終 止 コ ド ン か ら ア ミ ノ 酸 指 定 コ ド ンへ の 変 化 は,す べ 対 応 す る こ と を 見 い だ し た14).さ で 説 明 で き る で あ ろ う.ま に か か わ るtRNAGlyUCU遺 伝 子 を 検 出 し,こ Glyコ 翻 訳 に か か わ るtRNAGlyUCC遺 の 変 化 は,こ た,AUAのIleか の 暗 号 を解 読 す るtRNAの
More informationCHEMOTHERAPY
CHEMOTHERAPY VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin CHEMOTHERAPY AUG. 1993 VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin Table 1. Comparative in vitro activity of teicoplanin
More informationJpn J Electroph 1996; 40: 299
Jpn J Electroph 1996; 40: 299 Jpn J Electroph 図1. ミ ト コ ン ド リ ア3243位 3243位 がGに 変 異 (A G) 変 異 す る と, 制 限 酵 素ApaIに 1996; 40: 301 の 解 析. よ る認 識 サ イ トが 現 れ るの で, 酵 素 で 切 断 され, 137bpサ イ ズ が 検 出 され る. この 測
More informationVOL.30 NO.12 CHEMOTHERAPY Fig. 1 Effect of temperature on the growth curve of A. calcoaceticus A. calcoaceticits Ac 54 A. calcoacetictts Ac 164 Fig. 2 Effect of medium ph on the growth curve of A. calcoaceticus
More information9 Nippon Shokuhin Kagaku Kogaku Kaishi Vol. /,, No.0,,/+,/0 (,**/) 251 * * E#ects of Microbial Transglutaminase on Melting Point and Gel property of G
9 Nippon Shokuhin Kagaku Kogaku Kaishi Vol. /,, No.0,,/+,/0 (,**/) 251 * * E#ects of Microbial Transglutaminase on Melting Point and Gel property of Gelatins Takahiko Soeda, Tomoko Kaneko*, Akiko Hokazono,
More information988 CHEMOTHERAPY NOV. 1971
988 CHEMOTHERAPY NOV. 1971 VOL. 19 NO. 8 CHEMOTHERAPY 989 Effect of medium-ph and inoculum size on activity of SB-PC heart infusion agar, mcg/ml Sensitivity distribution of Staphylococci to SB-PC in surgical
More information日本化学療法学会雑誌第66巻第2号
173 Table 1.Detection rates of Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium, Ureaplasma urealyticum, Haemophilus influenzae and adenovirus from male urethritis in Urethritis No.
More informationTable 1.Concentration of gatifloxacin (Middle-ear) Table 2.Concentration of gatifloxacin (Paranasal sinuses) Table 3.Concentration of gatifloxacin (Tonsil) Table 4.No.of patients studied Table 5.Background
More informationCHEMOTHERAPY Table 1 Clinical effect of Sultamicillin
CHEMOTHERAPY CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin CHEMOTHERAPY Fig. 1 MICs of sultamicillin against respiratory pathogenic Branhamella catarrhalis 62 strains, inoculum size 106CFU/m1 Fig.
More informationCHEMOTHERAPY NOV S. aureus, S. epidermidis, E. coli, K. pgeumoniae, E. cloacae, S. marcescens, P. mirabilis, Proteus, P. aeruginosa Inoculum siz
VOL.33 S-5 CHEMOTHERAPY 381 Fig. 1 Chemical structure of HAPA-B Chemical name 1-N-[(2S)-3-Amino-2-hydroxypropiony1]-4-0-(6-amino- 6-deoxy-a-D-glucopyranosyl)-6-013-deoxy-4-C-methyl- 3-(methylamino)-ƒÀ-L-arabinopyranosyl]-2-deoxystreptamine
More informationKey words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection
Key words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection Table 1. Bacterial cell counts in feces of mice infected with Esclwrichia coli O 157: H7 NK2 before and during oral dosing with fosfomycin
More informationcoccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, F
VOL.43 S-1 coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, Flavobacter- Table 1. Concentration of grepafloxacin
More informationuntitled
11-19 2012 1 2 3 30 2 Key words acupuncture insulated needle cervical sympathetick trunk thermography blood flow of the nasal skin Received September 12, 2011; Accepted November 1, 2011 I 1 2 1954 3 564-0034
More information15) Egawa, R., Sawai, T. and Mit.uhashi, S.: Jap. J. Microbiol., 11 : 173-178, 1967. 16) Tanaka, T. and Hashimoto, H., Nagai, Y. and Mitsuhashi, S.: Jap. J. Microbiol., 11: 155-162, 1967. 17) Mitsuhashi,
More informationVOL.32 S-9 CHEMOTHERAPY Table 1 Minimum inhibitory concentrations of AC-1370, CPZ and CAZ Table 2 Efficacy of AC-1370 and CPZ against systemic infections in mice *Inoculum size: 106 cells/ml * 95% confidence
More informationCHEMOTHERAPY JUN Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter cloacae 27, Proteus rettgeri 7, Proteus inconstans 20, Proteus
VOL. 32 S-4 CHEMOTHERAPY Fig. 1 Chemical structure of sodium cefoperazone Fig. 2 Chemical structure of sodium cefoperazone CHEMOTHERAPY JUN. 1984 Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter
More informationCHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates
VOL.39 S-1 CHEMOTHERAPY FEB. 1981 Table 1. Activity of cefpirome and others against clinical isolates VOL.39 S-1 CHEMOTHERAPY FEB. 1991 72 M, 55.5 kg 66 F, 53 kg Chronic bronchitis Bronchopneumonia Peak
More informationTable 1.Resistance criteria Fig.1.The resistance rates of piperacillin,ceftazidime, cefsulodin,imipenem,aztreonam,gentamicin,tobramycin,amikacin,isepamicin,fosfomycin and ofloxacin against 2,793 strains
More informationCHEMOTHERAPY APR. 1984
VOL.32 S-3 CHEMOTHERAPY dihydro-4-oxo-7-(1-piperazinyl)-1, 8-naphthyridine- CHEMOTHERAPY APR. 1984 VOL.32 S-3 CHEMOTHERAPY Table 1 Implantation rates and post- implantation survival rates in females mated
More informationKey words : influenza, nested-pcr, serotype
Key words : influenza, nested-pcr, serotype Table 1 Sequence of PCR primers used to detect HA gene of influenza virus 524 清水 Fig. 1 Detection of PCR product 英明 他 (lstpcr) Table 2 Results method Fig. 2
More information.i...j...[.X8-2
Vol. 8 No.2 Nov. 2007 1 2 4 12 20 37 45 54 56 62 1 2 3 4 5 7 6 8 9 10 11 13 12 15 14 17 16 19 18 21 20 Hatena 23 22 Oidiodendron Oidiodendron 25 24 Monosiga ovata Monosiga 27 26 Toxoplasma gondii 29 28
More informationTable1MIC of BAY o 9867 against standard strains
Table1MIC of BAY o 9867 against standard strains Fig.2Cumulative and Distribution Curves of MIC (S.aureus 54 strains) 106cfu/ml Fig.3Correlogram of MIC (S.aureus 54 strains) CHEMOTHERAPY 451 Fig.4Cumulative
More informationCHEMOTHERAPY APRIL 1992 Table 2. Concentration of meropenem in human prostatic fluid Table 1. Background of 21 chronic complicated UTI cases * NB + BPH, NB + Kidney tumor, NB + Kidney tuberculosis Table
More informationThe Phase Behavior of Monooleoylglycerol-Water Systems Mivoshi Oil & Fat Co.. Ltd. Faculty of Science and Technology, Science University of Tokyo Inst
The Phase Behavior of Monooleoylglycerol-Water Systems Mivoshi Oil & Fat Co.. Ltd. Faculty of Science and Technology, Science University of Tokyo Institute of Colloid and Interface Science, Science University
More informationCHEMOTHERAPY Fig. 1 Body weight changes of pregnant mice treated orally with AM- 715 Day of sestation
CHEMOTHERAPY CHEMOTHERAPY Fig. 1 Body weight changes of pregnant mice treated orally with AM- 715 Day of sestation CHEMOTHERAPY Table 1 Preliminaly test of AM- 715 1): Mean } SD *: Significant difference
More informationTHE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterococcus avium 5Š, Corynebacterium xerosis 10Š, Corynebacterium pseudodiphtheriticum 10Š, Corynebacterium
THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterobacter spp., Serratia spp., Burkholderia cepacia, Flavobacterium spp., Alcaligenes spp. THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterococcus avium 5Š, Corynebacterium
More informationTable 1 Survival rates of infected mice given antibiotic doses producing peak serum a) S. aurcus Smith Challenge dose :7 ~10 (5% mucin) CFU/mouse. LD50: 1 ~103 (5% mucin) CFU/mouse. Table 2 Survival rates
More information37-4.indd
ISSN 0916-3328 東京大学アイソトープ総合センター VOL. 37 NO. 4 2007. 3. 26 アイソトープ総合センターの将来展望 40 18 18 20 3 800 1/3 1300 14 18 20 3 19 2 生きた細胞内の分子過程を 時間 空間計測する蛍光プローブの開発 1. はじめに Fura-2 Fura-2 198 1, 2 3, 4 2. 生体脂質分子の機能とその分析
More informationuntitled
Fig.1 t O O N,N p n J J J J J t J J J J J J J J J J J t t J J J J J J J J J p Fig.2 p t Fig.3 Fig.4 synanti p Table1 Table2t Table2 synanti antisyn synanti synanti Fig.5 syn anti anti Fig.6 Table3 Table4
More informationTable 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone
Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone (inoculum size= 106 CFU/ml) (Ĉ-lactamase producer : 2 strains) Fig. 1. Sensitivity distribution of
More information366 12 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 1 8 DNA 2,3 16 12 20 171 2008 12 2010 11 2 3,558 4.44% 1.65% 1.17% 90% 9 Escherichia coli -
Dec. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 365 11 sita oxacin 1 1 1 1 1 1 2 2 3 3 1 1 1 2 3 2012 9 14 sita oxacin STFX 50 mg 10% 2008 1 2008 12 2010 11 2 STFX 1,452 91.4% 1,235/1,351 95.9% 466/486
More informationCHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels of mezlocillin
CHEMOTHERAPY Fig. 2 Urinary excretion of mezlocillin Fig. 1 Blood levels of mezlocillin CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels
More informationTable 1.Quality control of MICs for reference strains Table 2.Antimicrobial activity of gatifloxacin against aerobic bacteria Table 4.Antimicrobial activity of gatifloxacin and other quinolones against
More informationuntitled
2010 58 1 39 59 c 2010 20 2009 11 30 2010 6 24 6 25 1 1953 12 2008 III 1. 5, 1961, 1970, 1975, 1982, 1992 12 2008 2008 226 0015 32 40 58 1 2010 III 2., 2009 3 #3.xx #3.1 #3.2 1 1953 2 1958 12 2008 1 2
More informationTable 1 Patients with various renal function * Ccr, Creatinine clearance ml/min per 1. 48 m2 ** C.V.D., Cerebral vascular disease ; C.R F., Chronic renal failure ; H.D., Hemoclialysis ; D., Dialyzer ;
More informationKey words: change serotype, Pseudomonas aeruginosa anti-pseudomonal drug,
Key words: change serotype, Pseudomonas aeruginosa anti-pseudomonal drug, Table 1 Incidence of changes in serotype of Pseudomonas aeruginosa isolates induced by anti-pseudomonal drugs Number of isolates
More informationYeast one-hybrid system niimi@agr.nagoya-u.ac. jp て い る しか し す べ て のDNA結 合 タンパク 質 が 酵 母 で 転 写 活 性 化 因 子 と して 働 く と は限 らな い この 場 合 に は VPI6やGa14の 転写活 性 化 領 域 と のfusionタ ン パ ク質 を作 る こ と に よって酵母 で転写活 性化
More information(1) GGT阻害剤
(GGT) (glutathione, GSH, -L-Glu-L-Cys-Gly) Cys 1 10 mm GSSG GSH 98% - + H 3 N COO - γ- O H N O N H SH O γ-glu Cys Gly OH - (GGT, EC 2.3.2.2) GGT (GSH) GSX - Glu Cys(X)-Gly 1-2) GGT - 1 hydrolases transferases
More informationA STUDY ON GENITAL SKIN ANDROGEN RECEPTOR BY DISPERSED CELL METHOD Yasukazu Sen and Masaaki Morioka Department of Urology, Kochi Medical School, Nankoku, Japan (Director: Prof. Yukitoshi Fujita) Yoshiteru
More informationCHEMOTHERAPY Fig. 1 Chemical structure of CXM-AX
Fig. 1 Chemical structure of CXM-AX NOV. 1986 Fig. 2 Sensitivity distribution of clinical isolates organisms (106 cells/ml) a Smurcus 27 strains d) P.m irabilis 15 strains b Ecol i 27 strains 111.morganii
More informationDatabase Center for Life Science Online Service Natuo Komoto, jp Silkworm mutants
Natuo Komoto, E-mail : natuo@affrc.go. jp http://cse.nias.affrc.go.jp/natuo/index.htm Silkworm mutants whose deficiency of epidermal orate granules causes translucent larval skin phenotypes 図3 カイ コ幼 虫
More information1 Fig. 1 Extraction of motion,.,,, 4,,, 3., 1, 2. 2.,. CHLAC,. 2.1,. (256 ).,., CHLAC. CHLAC, HLAC. 2.3 (HLAC ) r,.,. HLAC. N. 2 HLAC Fig. 2
CHLAC 1 2 3 3,. (CHLAC), 1).,.,, CHLAC,.,. Suspicious Behavior Detection based on CHLAC Method Hideaki Imanishi, 1 Toyohiro Hayashi, 2 Shuichi Enokida 3 and Toshiaki Ejima 3 We have proposed a method for
More informationDatabase Center for Life Science Online Service
50 蛋白質 核酸 酵素 Vol.44No.11 1999 三 級 ア ミ ンの 誘 導 体 は 四 級 ア ミ ン の 誘 導 体 よ り も導 入 導 入 効 率 を 与 え る こ と を 最 近 発 見 し た この 親 水 性 側 効 率 が 高 い ② 末 端 の ア ル キ ル 基 が か さ高 くな る 大 鎖 末 端 基 を も った コ レス テ ロー ル 誘 導 体Ⅱ き くな
More information会報35号表紙.pdf
35 No. (2017 1 ) RNA 2017 2017 TV 365 365 chunky 26 RNA 2017 Congratulations26 30-1 - RNA 2017-2 - - 3 - - 4 - - 5 - - 6 - 2016 8 31 9 2 RNA 2016 1 RNA RNA RNA RNA RNA 1-7 - RNA RNA 3 3 7 31 RNA ncrna
More informationCHEMOTHERAPY APR Fig. 2 The inactivation of aminoglycoside antibiotics by PC-904 Fig. 3 Serum concentration of PC-904 (1) Fig. 4 Urinary recover
VOL.26 S-2 CHEMOTHERAPY Gentamicin (GM), Dibekacin (DKB), Tobramycin Fig. 1 Protein concentration and protein binding rate Table 2 Protein binding rate of PC-904 in serum of healthy adults, and patients
More informationKey Words: Klebsiella pneumoniae, CEP-AIS, MIC, "MBC", MIC of drugs in combination
Key Words: Klebsiella pneumoniae, CEP-AIS, MIC, "MBC", MIC of drugs in combination Fig. 1. The following three kinds of overnight broth cultures of 10 strains of Kl. pneumoniae were inoculated on the agar
More informationJournal of Geography 116 (6) Configuration of Rapid Digital Mapping System Using Tablet PC and its Application to Obtaining Ground Truth
Journal of Geography 116 (6) 749-758 2007 Configuration of Rapid Digital Mapping System Using Tablet PC and its Application to Obtaining Ground Truth Data: A Case Study of a Snow Survey in Chuetsu District,
More informationThe Evaluation on Impact Strength of Structural Elements by Means of Drop Weight Test Elastic Response and Elastic Limit by Hiroshi Maenaka, Member Sh
The Evaluation on Impact Strength of Structural Elements by Means of Drop Weight Test Elastic Response and Elastic Limit by Hiroshi Maenaka, Member Shigeru Kitamura, Member Masaaki Sakuma Genya Aoki, Member
More informationStudies of Foot Form for Footwear Design (Part 9) : Characteristics of the Foot Form of Young and Elder Women Based on their Sizes of Ball Joint Girth
Studies of Foot Form for Footwear Design (Part 9) : Characteristics of the Foot Form of Young and Elder Women Based on their Sizes of Ball Joint Girth and Foot Breadth Akiko Yamamoto Fukuoka Women's University,
More informationVOL. 36 S-3 CHEMOTHERAPY 437
VOL. 36 S-3 CHEMOTHERAPY 437 438 CHEMOTHERAPY JULY 1988 Fig. 1 Contractile response of gastrointestinal tract to intravenous administration of saline and EM in interdigestive state in dogs (a) : Saline,
More information123-099_Y05…X…`…‘…“†[…h…•
1. 2 1993 2001 2 1 2 1 2 1 99 2009. 1982 250 251 1991 112 115 1988 75 2004 132 2006 73 3 100 3 4 1. 2. 3. 4. 5. 6.. 3.1 1991 2002 2004 3 4 101 2009 3 4 4 5 1 5 6 1 102 5 6 3.2 2 7 8 2 X Y Z Z X 103 2009
More informationCHEMOTHERAPY FEB Table 1 Background of volunteers
CHEMOTHERAPY FEB. 1985 Table 1 Background of volunteers Table 3 Reproducibility of saisomicln In the EIA and the RIA Fig.1 Comparison of the EIA with the RIA or bioassay of sisomicin Table 4 Blood levels
More informationTable 1. Antimicrobial drugs using for MIC
Table 1. Antimicrobial drugs using for MIC Table 2. Susceptibilities determined with the VITEK 2 system and agar dilution reference by interpretive eategory for Staphylococcus aureus Table 3. Interpretive
More information22 610407487 ロ ペ ミ ッ ク 小 児 用 0. 0 5 % 2319001C1072 23 610412059 ゲ シ ン L 錠 5 0 m g 2478001G1046 24 610412105 ソ レ ル モ ン S R カ プ セ ル 3 7. 5 m g 1147002N1
お 知 ら せ ( 薬 ) 0 0 5 平 成 2 0 年 8 月 2 9 日 医 薬 品 マ ス タ ー の 改 定 に つ い て 今 般 下 記 の と お り 医 薬 品 マ ス タ ー を 改 定 し ま し た の で お 知 ら せ し ま す 記 次 の 医 薬 品 に つ い て は 平 成 2 0 年 3 月 5 日 付 け 厚 生 労 働 省 告 示 第 7 2 号 に 基 づ
More informationEVALUATION OF NOCTURNAL PENILE TUMESCENCE (NPT) IN THE DIFFERENTIAL DIAGNOSIS OF IMPOTENCE Masaharu Aoki, Yoshiaki Kumamoto, Kazutomi Mohri and Kazunori Ohno Department of Urology, Sapporo Medical College
More informationDevelopement of Plastic Collocation Method Extension of Plastic Node Method by Yukio Ueda, Member Masahiko Fujikubo, Member Masahiro Miura, Member Sum
Developement of Plastic Collocation Method Extension of Plastic Node Method by Yukio Ueda, Member Masahiko Fujikubo, Member Masahiro Miura, Member Summary Previously, the authors developed the plastic
More informationDatabase Center for Life Science Online Service
図8SINEの SINEと3'末 親 と な って い るLINEの 系 統 関係 端 を共 有 して い るLINEは 赤 色 で 示 す, 報 告 さ れ て い るす べ て のLINEは11の ら れ る.そ れ ぞ れ のLINEの グル ー プ に分 け あ い だ にお い て 水 平 的 な交 流 が な い と仮 定 す る と,こ の11に 分 け られ る こ のLINE え
More information1) Y. Kobuke, K. Hanji, K. Horiguchi, M. Asada, Y. Nakayama, J. Furukawa, J. Am. Chem. Soc., 98, 7414(1976). 2) S. Yoshida, S. Hayano, J. Memb. Sci.,
1) Y. Kobuke, K. Hanji, K. Horiguchi, M. Asada, Y. Nakayama, J. Furukawa, J. Am. Chem. Soc., 98, 7414(1976). 2) S. Yoshida, S. Hayano, J. Memb. Sci., 11, 157(1982). 3) J. D. Lamb, J. J. Christensen, J.
More information1) i) Barber, M. et al.: Brit. Med J, 2, 565, 19'49. ii) Barber, M.F.G. J. Hayhoe and J. E. M. Whithead: Lancet, 1120 `1125, 1949.-2) Bergey: Bergey's Manual of Determinative Bacteriology 7 th Ed: (1958).-3)
More informationMicrosݯft Word - 91 forܠ2009November.docx
特 集 : Query & Analysis の 仕 訳 転 送 機 能 SunSystems と 連 携 し て 使 用 す る こ と が で き る Infor Performance Management Query&Analysis( 以 下 Q&A) ( 旧 : SunSystems Vision ) と い う 製 品 が あ り ま す Q&A は Microsoft Excel の
More informationFig. 1 Structure of a Sebaceous Follicle (Ref.1).
Importance and Countermeasures for Sebum Control in Application of Makeup Cosmetics Koichi NOMURA POLA Chemical Industries, Inc., R&D Planning Department 27-1, Takashimadai, Kanagawa-ku, Yokohama 221-0833,
More information1) The Ribosome : Structure, Function and Evolu tion (ed. Hill, W. E., Dahlberg, A., Gerret, R. A. Moore, P. B., Schlessinger, D., Warner, J. R. American Society for Microbiology, Washington D.C. (1990)
More informationMinamiooya, Machida, Tokyo 194, Japan] RNA World, A Key Step in the Origin of Life : Inspection from the View Point of Biological Evolution 1) Crick, F. H. C.: Sym. Soc. Exp. Biol., 12, 548-555
More informationJ. Soc. Cosmet. Chem. Jpn. 7-chome, Edogawa-ku, Tokyo 132, Japan 2.1 J. Soc. Cosmet. Chem. Japan. Vol. 31, No
J. Soc. Cosmet. Chem. Jpn. 7-chome, Edogawa-ku, Tokyo 132, Japan 2.1 J. Soc. Cosmet. Chem. Japan. Vol. 31, No. 2 1997 167 Fig.-1 Balanced fiber method Fig.-2 The effects of perming and IG on breaking off
More information474 Nippon Shokuhin Kagaku Kogaku Kaishi Vol. /-, No.3,.1..2* (,**0) 24 Measurement of Deterioration of Frying Oil Using Electrical Properties Yoshio
474 Nippon Shokuhin Kagaku Kogaku Kaishi Vol. / No.3.1..2 (0) 24 Measurement of Deterioration of Frying Oil Using Electrical Properties Yoshio Hagura Yoshihiro Sasaki and Kanichi Suzuki Graduate School
More informationFig. 1. Structure of [methyl-14c]zonisamide
Key words : Zonisamide, Metabolism, Plasma, Erythrocytes, Preputial gland, Urine, Bile, Rat, Dog, Monkey Metabolism of ["Clzonisamide in rats, dogs and monkeys Katashi MATSUMOTO, Koji YOSHIDA, Toshihiko
More information1 LINE31.1 28.010.3 37.4 24.9 10 9 8 7 6 5 3 1 88.9 77.7 66.7 64.1 62.9 61.3 56.5 56.4 42.2 31.7 28.0 31.1 31.5 30.4 28.6 20.7 16.8 15.9 13.5 10.3 7.9
2014 SNSFacebook Twitter SNS 2014 4 52.8 20 ~ 1 ~ 1 LINE31.1 28.010.3 37.4 24.9 10 9 8 7 6 5 3 1 88.9 77.7 66.7 64.1 62.9 61.3 56.5 56.4 42.2 31.7 28.0 31.1 31.5 30.4 28.6 20.7 16.8 15.9 13.5 10.3 7.9
More information10中西_他.indd
Streptomyces mobaraensis N N N Sm b Sm N N Sm Sm Sm ' ' Sm Sm ak K k K bk k K Sm Sm a b S. mobaraensis a b a b Sm b b bb b b Sm Sm S. lividans ab Sm ab Sm ab ab ab ab SmSm S. lividansab S. lividans ab
More informationBy Kenji Kinoshita, I taru Fukuda, Taiji Ota A Study on the Use of Overseas Construction Materials There are not few things which are superior in the price and the aspect of the quality to a domestic
More information浜松医科大学紀要
On the Statistical Bias Found in the Horse Racing Data (1) Akio NODA Mathematics Abstract: The purpose of the present paper is to report what type of statistical bias the author has found in the horse
More information/‚“1/ŒxŒ{‚×›î’æ’¶
60 1 pp.3-8 2010 1. H1N1 1) 2) 3) 4) ERATO 2009 H1N1 21 H1N1 HA PB2 2009 3 Pandemic H1N1 2009 WHO 6 11 21 2009 11 2010 4 21 H1N1 H1N1 2009 4 15 CDC 108-8639 4-6-1 TEL: 03-5449-5281 FAX: 03-5449-5408 E-mail:
More information